« Previous article
US FDA Authorize Dir...

5th March 2021  Product update: rapidvirology staff writer

COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants

Seegene has developed a variant diagnostic test that can simultaneously detect COVID-19 and screen multiple virus variants, with a single multiplex real-time PCR test.

The 'Allplex™ SARS-CoV-2 Master Assay' can detect both coronavirus and its variants in the initial round of testing.

This new COVID-19 test detects a total of 10 targets including four coronavirus genes (E gene, RdRP gene, N gene and S gene) as well as five virus variants.

Those variants include: 

  • B.1.1.7 (U.K. lineage of concern, associated with the N501Y mutation)

  • B.1.351 (South African lineage defined by 501Y.V2)

  • P.1 (Brazilian lineage with variants of biological significance E484K, N501Y and K417T)

  • B.1.1.207 (U.S. lineage)

Seegene's technology can precisely detect various types of mutant variants including those of point mutation and amino acid deletion.

Additionally, Seegene's 'Allplex™ SARS-CoV-2 Master Assay' can pre-screen suspicious new variants that may carry these mutations.

Recently, multiple COVID-19 mutations have been reported to overlap, like the N501Y mutation, now being spotted in multiple lineages, after having been reported in the U.K. and South African variants.

'Allplex™ SARS-CoV-2 Master Assay' can also be used in conjunction with 'Allplex™ RV Essential Assay,' a one-step assay for screening 17 target causative viruses for respiratory infections.

With a single swab sample, the two provide high usability in detecting essential respiratory pathogens accurately and comprehensively.

Seegene also utilized its original technology of an endogenous internal control system that verifies the entire testing process, starting with the sample collection, making the less-invasive saliva sampling method a viable option.

The company also have an extraction-free application that is currently under development. The extraction-free method can shorten the testing process and eliminate concerns over possible extraction reagent and consumable shortages.

By incorporating Seegene's proprietary high multiplex technology, Seegene becomes the first in the market to target both COVID-19 and variants with a single tube of reagent.

The company already has over 150 multiplex diagnostic tests in its portfolio including HPV and STI assays.

With the company's big data auto-surveillance in silico system, the diagnostic firm said it closely monitors and analyzes global databases on the coronavirus and its variants, enabling swift response with further product development.

The need to screen COVID-19 variants has become an essential tool in effectively controlling infections and handling patient care, following worrisome developments that some COVID-19 vaccines produce a weakened immune response against the contagious virus variants.

Seegene previously introduced 'Allplex™ SARS-CoV-2 Variants Ⅰ Assay,' a diagnostic test capable of identifying origins of multiple variants.

This particular test can detect and differentiate virus variations that seem to have originated from the UK, South Africa, Japan and Brazil as well as additional suspicious variants.



Date Published: 5th March 2021

Source article link: View

Note: This content has been edited by a rapidvirology.com staff writer for style and content.

View full company details

Related news